Charlotte R. Williams

4.5k total citations
41 papers, 3.6k citations indexed

About

Charlotte R. Williams is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Charlotte R. Williams has authored 41 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 13 papers in Oncology and 10 papers in Genetics. Recurrent topics in Charlotte R. Williams's work include Genomics, phytochemicals, and oxidative stress (17 papers), Estrogen and related hormone effects (9 papers) and Natural product bioactivities and synthesis (8 papers). Charlotte R. Williams is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (17 papers), Estrogen and related hormone effects (9 papers) and Natural product bioactivities and synthesis (8 papers). Charlotte R. Williams collaborates with scholars based in United States, United Kingdom and Netherlands. Charlotte R. Williams's co-authors include Michael B. Sporn, Karen T. Liby, Renee Risingsong, Nanjoo Suh, Darlene B. Royce, Gordon W. Gribble, Tadashi Honda, Albena T. Dinkova‐Kostova, Katherine K. Stephenson and Mark M. Yore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Charlotte R. Williams

41 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charlotte R. Williams United States	32	2.8k	480	462	329	289	41	3.6k
Renee Risingsong United States	26	2.0k 0.7×	356 0.7×	354 0.8×	239 0.7×	219 0.8×	30	2.5k
Dong Xiao China	34	2.8k 1.0×	451 0.9×	660 1.4×	216 0.7×	363 1.3×	88	3.8k
Lynne Howells United Kingdom	28	2.1k 0.8×	765 1.6×	570 1.2×	180 0.5×	249 0.9×	62	3.9k
Rong Hu United States	25	2.2k 0.8×	371 0.8×	266 0.6×	167 0.5×	257 0.9×	44	2.9k
Sung‐Gook Cho South Korea	27	1.3k 0.5×	403 0.8×	315 0.7×	147 0.4×	165 0.6×	60	2.2k
Mark M. Yore United States	19	2.2k 0.8×	165 0.3×	257 0.6×	173 0.5×	275 1.0×	21	3.1k
Anjana Bhardwaj United States	17	1.4k 0.5×	377 0.8×	440 1.0×	188 0.6×	273 0.9×	37	2.6k
Cristina M. Rondinone United States	37	2.7k 1.0×	250 0.5×	221 0.5×	201 0.6×	496 1.7×	74	4.8k
Fawaz G. Haj United States	42	3.0k 1.1×	380 0.8×	334 0.7×	208 0.6×	1.1k 3.8×	87	5.7k
K. Eric Paulson United States	32	2.0k 0.7×	401 0.8×	381 0.8×	327 1.0×	281 1.0×	42	3.1k

Countries citing papers authored by Charlotte R. Williams

Since Specialization

Citations

This map shows the geographic impact of Charlotte R. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte R. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte R. Williams more than expected).

Fields of papers citing papers by Charlotte R. Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte R. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte R. Williams. The network helps show where Charlotte R. Williams may publish in the future.

Co-authorship network of co-authors of Charlotte R. Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte R. Williams. A scholar is included among the top collaborators of Charlotte R. Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte R. Williams. Charlotte R. Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leal, Ana S., Charlotte R. Williams, Darlene B. Royce, et al.. (2017). Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Letters. 394. 76–87. 96 indexed citations

Royce, Darlene B., et al.. (2015). The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice. Cancer Prevention Research. 9(1). 105–114. 19 indexed citations

Canfield, Kaleigh, Jiaqi Li, Owen M. Wilkins, et al.. (2015). Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 14(4). 648–655. 60 indexed citations

Williams, Charlotte R., et al.. (2015). Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacological Research. 100. 135–147. 26 indexed citations

To, Ciric, Carol S. Ringelberg, Darlene B. Royce, et al.. (2015). Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis. 36(7). 769–781. 60 indexed citations

To, Ciric, Eun‐Hee Kim, Darlene B. Royce, et al.. (2014). The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice. Cancer Prevention Research. 7(7). 698–707. 60 indexed citations

Tran, Kim‐Vy, Renee Risingsong, Darlene B. Royce, et al.. (2012). The Synthetic Triterpenoid CDDO-Methyl Ester Delays Estrogen Receptor–Negative Mammary Carcinogenesis in Polyoma Middle T Mice. Cancer Prevention Research. 5(5). 726–734. 40 indexed citations

Risingsong, Renee, Darlene B. Royce, Charlotte R. Williams, et al.. (2012). The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis. 34(1). 199–210. 40 indexed citations

Kaidery, Navneet Ammal, Rebecca Banerjee, Lichuan Yang, et al.. (2012). Targeting Nrf2-Mediated Gene Transcription by Extremely Potent Synthetic Triterpenoids Attenuate Dopaminergic Neurotoxicity in the MPTP Mouse Model of Parkinson's Disease. Antioxidants and Redox Signaling. 18(2). 139–157. 138 indexed citations

10.

Liby, Karen T., Darlene B. Royce, Renee Risingsong, et al.. (2010). Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer. Cancer Prevention Research. 3(11). 1427–1434. 78 indexed citations

11.

Stack, Cliona, Daniel Ho, Elizabeth Wille, et al.. (2010). Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine. 49(2). 147–158. 143 indexed citations

12.

Liby, Karen T., Renee Risingsong, Darlene B. Royce, et al.. (2009). Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice. Cancer Prevention Research. 2(12). 1050–1058. 50 indexed citations

13.

Liby, Karen T., Renee Risingsong, Darlene B. Royce, et al.. (2008). Prevention and Treatment of Experimental Estrogen Receptor–Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268. Clinical Cancer Research. 14(14). 4556–4563. 66 indexed citations

14.

Liby, Karen T., Darlene B. Royce, Renee Risingsong, et al.. (2006). The triterpenoid, CDDO-methyl ester, and the rexinoid, LG100268, synergize in the prevention of mammary tumors in a mouse model of estrogen receptor-negative breast cancer.. Cancer Epidemiology and Prevention Biomarkers. 15. 1 indexed citations

15.

Honda, Tadashi, Karen T. Liby, Chitra Sundararajan, et al.. (2006). Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorganic & Medicinal Chemistry Letters. 16(24). 6306–6309. 40 indexed citations

16.

Coleman, Michael D., Charlotte R. Williams, & Guido R.M.M. Haenen. (2006). Effects of Lipoic Acid and Dihydrolipoic Acid on 4‐Aminophenol‐Mediated Erythrocytic Toxicity in vitro*. Basic & Clinical Pharmacology & Toxicology. 99(3). 225–229. 5 indexed citations

17.

Liby, Karen T., Thomas Hock, Mark M. Yore, et al.. (2005). The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling. Cancer Research. 65(11). 4789–4798. 239 indexed citations

18.

Suh, Nanjoo, Anita B. Roberts, Stephanie Birkey Reffey, et al.. (2003). Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.. PubMed. 63(6). 1371–6. 76 indexed citations

19.

Place, Andrew E., Nanjoo Suh, Charlotte R. Williams, et al.. (2003). The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.. PubMed. 9(7). 2798–806. 124 indexed citations

20.

Suh, Nanjoo, William W. Lamph, Andrew L. Glasebrook, et al.. (2002). Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.. PubMed. 8(10). 3270–5. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact